Literature DB >> 21687489

Fighting breast cancer: a call for a new paradigm.

Mark Binstock.   

Abstract

Entities:  

Year:  2005        PMID: 21687489      PMCID: PMC3108419          DOI: 10.7812/TPP/04-108

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


× No keyword cloud information.
  21 in total

1.  ACOG practice bulletin. Prophylactic oophorectomy. Number 7, September 1999 (replaces Technical Bulletin Number 111, December 1987). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetricians and Gynecologists.

Authors: 
Journal:  Int J Gynaecol Obstet       Date:  1999-12       Impact factor: 3.561

2.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.

Authors:  Andrew N Freedman; Barry I Graubard; Sowmya R Rao; Worta McCaskill-Stevens; Rachel Ballard-Barbash; Mitchell H Gail
Journal:  J Natl Cancer Inst       Date:  2003-04-02       Impact factor: 13.506

3.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

4.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

Review 5.  Application of breast cancer risk prediction models in clinical practice.

Authors:  Susan M Domchek; Andrea Eisen; Kathleen Calzone; Jill Stopfer; Anne Blackwood; Barbara L Weber
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

6.  Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

Authors:  T R Rebbeck; A M Levin; A Eisen; C Snyder; P Watson; L Cannon-Albright; C Isaacs; O Olopade; J E Garber; A K Godwin; M B Daly; S A Narod; S L Neuhausen; H T Lynch; B L Weber
Journal:  J Natl Cancer Inst       Date:  1999-09-01       Impact factor: 13.506

7.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

Authors:  Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

8.  Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force.

Authors:  Linda L Humphrey; Mark Helfand; Benjamin K S Chan; Steven H Woolf
Journal:  Ann Intern Med       Date:  2002-09-03       Impact factor: 25.391

9.  Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.

Authors:  Mieke Kriege; Cecile T M Brekelmans; Carla Boetes; Peter E Besnard; Harmine M Zonderland; Inge Marie Obdeijn; Radu A Manoliu; Theo Kok; Hans Peterse; Madeleine M A Tilanus-Linthorst; Sara H Muller; Sybren Meijer; Jan C Oosterwijk; Louk V A M Beex; Rob A E M Tollenaar; Harry J de Koning; Emiel J T Rutgers; Jan G M Klijn
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

10.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.